Study of Kidney Tumors in Young Patients
Study type: Observational What is this?
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Rochester, Minnesota: 07-000195
NCT ID: NCT00898365
Sponsor Protocol Number: AREN03B2
About this study
This laboratory study is looking at kidney tumors in young patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer. It may also help the study of cancer in the future.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.
See eligibility criteria
- Patients with the first occurrence of any tumor of the kidney identified on CT scan or MRI are eligible for this study; histologic diagnosis is not required prior to enrollment but is required for all patients once on study
- Eligible tumors include (but are not limited to):
- Nephroblastic tumors
- Nephroblastoma (Wilms' tumor) (favorable histology, anaplasia [diffuse, focal])
- Patients with extra-renal nephroblastoma allowed
- Nephrogenic rests and nephroblastomatosis
- Cystic nephroma and cystic partially differentiated nephroblastoma
- Metanephric tumors (metanephric adenoma, metanephric adenofibroma, metanephric stromal tumor)
- Mesoblastic nephroma (cellular, classic, mixed)
- Clear cell sarcoma
- Rhabdoid tumor (any malignant rhabdoid tumor occurring outside the CNS)
- Renal epithelioid tumors of childhood (papillary renal cell carcinoma, medullary renal cell carcinoma, renal tumors associated with Xp11.2 translocations, oncocytic renal neoplasms after neuroblastoma)
- Ossifying renal tumor of infancy
- Patients with the first occurrence of the following tumors are also eligible:
- Extrarenal nephroblastoma
- Malignant rhabdoid tumor occurring anywhere outside the Central Nervous System
- For ALL patients (with exception of bilateral, bilaterally predisposed or unilateral tumor in solitary kidney planning to enroll without biopsy), the following submissions are required:
- A complete set of recut H & E slides
- Representative formalin-fixed paraffin-embedded tissue block or if a block is unavailable, 10 unstained slides from a representative block of tumor
- Institutional pathology report, transmittal form and pathology checklist
- Copies of images and institutional reports of CT and/or MRI abdomen and pelvis
- Copies of images and institutional report of CT chest for all malignant tumors
- Institutional surgical report(s)
- Patients with extrarenal Wilms tumor must have tumor tissue available for central review
- Patients with extra-CNS malignant rhabdoid tumor must have tumor tissue available for central review
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Participating Mayo Clinic locations
Study statuses change often. Please contact us for help.
|Mayo Clinic Location
Mayo Clinic principal investigator
Carola A Arndt, M.D.
Open for enrollment
Cancer Center Clinical Trials Referral Office